Shandong Buchang Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Shandong Buchang Pharmaceuticals's earnings have been declining at an average annual rate of -49.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 3.6% per year.
Key information
-49.8%
Earnings growth rate
-49.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -3.6% |
| Return on equity | -4.3% |
| Net Margin | -2.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shandong Buchang Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11,776 | -293 | 5,726 | 364 |
| 30 Jun 24 | 11,719 | -196 | 5,973 | 357 |
| 31 Mar 24 | 12,371 | -22 | 6,679 | 344 |
| 31 Dec 23 | 13,245 | 319 | 7,373 | 335 |
| 30 Sep 23 | 13,630 | -1,871 | 7,825 | 199 |
| 30 Jun 23 | 14,811 | -1,602 | 8,467 | 285 |
| 31 Mar 23 | 15,266 | -1,504 | 8,471 | 275 |
| 31 Dec 22 | 14,951 | -1,530 | 8,391 | 284 |
| 30 Sep 22 | 15,690 | 1,282 | 8,921 | 384 |
| 30 Jun 22 | 15,475 | 1,162 | 8,871 | 337 |
| 31 Mar 22 | 15,612 | 1,313 | 9,254 | 377 |
| 31 Dec 21 | 15,763 | 1,289 | 9,252 | 409 |
| 30 Sep 21 | 16,140 | 1,739 | 9,117 | 540 |
| 30 Jun 21 | 16,357 | 1,905 | 9,289 | 531 |
| 31 Mar 21 | 16,718 | 1,962 | 9,514 | 563 |
| 31 Dec 20 | 16,007 | 1,861 | 9,213 | 533 |
| 30 Sep 20 | 15,257 | 1,993 | 8,851 | 578 |
| 30 Jun 20 | 14,886 | 2,049 | 8,775 | 563 |
| 31 Mar 20 | 14,011 | 1,966 | 8,513 | 496 |
| 31 Dec 19 | 14,255 | 1,946 | 8,864 | 505 |
| 30 Sep 19 | 14,621 | 2,022 | 9,297 | 311 |
| 30 Jun 19 | 14,322 | 1,986 | 9,138 | 392 |
| 31 Mar 19 | 14,117 | 1,966 | 9,049 | 448 |
| 31 Dec 18 | 13,665 | 1,888 | 8,735 | 480 |
| 30 Sep 18 | 13,705 | 1,724 | 8,958 | 601 |
| 30 Jun 18 | 13,860 | 1,661 | 8,879 | 694 |
| 31 Mar 18 | 13,866 | 1,622 | 8,868 | 579 |
| 01 Jan 18 | 13,864 | 1,638 | 8,925 | 489 |
| 30 Sep 17 | 12,764 | 1,641 | 8,276 | 239 |
| 30 Jun 17 | 12,922 | 1,842 | 8,420 | 0 |
| 31 Mar 17 | 12,748 | 1,799 | 8,209 | 0 |
| 31 Dec 16 | 12,321 | 1,769 | 7,976 | 0 |
| 30 Sep 16 | 12,883 | 1,903 | 8,082 | 0 |
| 31 Dec 15 | 11,656 | 3,537 | 7,284 | 0 |
| 31 Dec 14 | 10,334 | 1,324 | 6,465 | 0 |
| 31 Dec 13 | 8,592 | 1,169 | 5,370 | 0 |
Quality Earnings: 603858 is currently unprofitable.
Growing Profit Margin: 603858 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603858 is unprofitable, and losses have increased over the past 5 years at a rate of 49.8% per year.
Accelerating Growth: Unable to compare 603858's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603858 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 603858 has a negative Return on Equity (-4.27%), as it is currently unprofitable.